Raltegravir
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Raltegravir and local guidelines before prescribing.
Integrase inhibitor
Mechanism
Integrase strand transfer inhibitor.
Uses
HIV infection.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Headache, nausea, raised CK, rash.
Interactions
Polyvalent cations reduce absorption; rifampicin.
Contraindications and cautions
Hypersensitivity
Monitoring
HIV viral load, CK
Pregnancy and breastfeeding
Used in pregnancy
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Take twice daily or 1200 mg once daily forms.
More from the textbook: uses, cautions and other points
- Integrase inhibitors | Dolutegravir , bictegravir , raltegravir, cabotegravir | Well tolerated; insomnia, headache, weight gain ; dolutegravir and bictegravir raise creatinine slightly (block its secretion - not true kidney damage); absorption reduced by antacids, calcium, iron, magnesium - separate doses
ID: HIV, viral hepatitis and blood-borne viruses - Usual regimen - tenofovir disoproxil–emtricitabine plus an integrase inhibitor (e.g. raltegravir).
ID: HIV, viral hepatitis and blood-borne viruses - Tenofovir–emtricitabine + raltegravir | HIV PEP for 28 days, within 72 hours.
ID: HIV, viral hepatitis and blood-borne viruses
Where it is discussed in the book
- ID: HIV, viral hepatitis and blood-borne viruses (3 mentions)